AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read

Alto Neuroscience President And CFO Sold Shares Worth Over $3.5M

Alto Neuroscience's President and CFO, Nicholas Conrad Smith, sold shares worth $3.57M under a 10b5-1 plan, at average prices of $26.58, $25.78, and $26.87. He now directly owns 24,060 shares, according to an SEC filing.

Original reporting
tradingview.com
Published Oct 2, 2026, 1:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 1:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alto Neuroscience President And CFO Sold Shares Worth Over $3.5M — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

Minor dilution of insider ownership; unlikely to move the stock significantly.

02

Market read

Routine insider sale with limited market impact.

03

What to watch

Potential upcoming dilution or secondary offering not disclosed.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filing by President and CFO of Alto Neuroscience reporting insider stock sales under a Rule 10b5-1 plan.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale may signal insider confidence despite the modest size.

Key entities

  • Company
    Alto Neuroscience

    Biotech firm whose President and CFO sold $3.5M of shares.

Read at source← All news

Related articles

AUG 12
$ANROMed

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoin

SEC EDGAR 8-K6 min
JUL 13
$ANROMed

Alto Neuroscience, Inc. (ANRO): Results of Operations and Financial Condition

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

SEC EDGAR 8-K3 min
OCT 2
$RKLBMed

RKLB Stock’s 2-Week Rally Is On The Line — But Cathie Wood’s ARK Is Loading Up As Wall Street Sees 55% Upside

Rocket Lab (RKLB) shares are down 5% this week, despite a 1% rise on Thursday. Cathie Wood's ARK funds bought $16.5M in RKLB shares. Analysts average a 'Strong Buy' rating with a $109.15 price target, implying 55% upside. Citi initiated coverage with a 'Buy' rating and $105 target. RKLB secured a 20-launch contract with Synspective, its largest commercial deal.

finance.yahoo.com2 min